- Home
- JHX vs BMRN Comparison
JHX vs BMRN Comparison
Compare JHX & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JHX
- BMRN
- Stock Information
- Founded
- JHX 1888
- BMRN 1996
- Country
- JHX Ireland
- BMRN United States
- Employees
- JHX N/A
- BMRN N/A
- Industry
- JHX Building Materials
- BMRN Biotechnology: Pharmaceutical Preparations
- Sector
- JHX Industrials
- BMRN Health Care
- Exchange
- JHX Nasdaq
- BMRN Nasdaq
- Market Cap
- JHX 11.3B
- BMRN 11.1B
- IPO Year
- JHX N/A
- BMRN 1999
- Fundamental
- Price
- JHX $19.26
- BMRN $55.14
- Analyst Decision
- JHX Strong Buy
- BMRN Buy
- Analyst Count
- JHX 7
- BMRN 24
- Target Price
- JHX $28.00
- BMRN $91.70
- AVG Volume (30 Days)
- JHX 8.9M
- BMRN 1.8M
- Earning Date
- JHX 11-11-2025
- BMRN 10-28-2025
- Dividend Yield
- JHX N/A
- BMRN N/A
- EPS Growth
- JHX N/A
- BMRN 154.69
- EPS
- JHX 0.77
- BMRN 3.40
- Revenue
- JHX $3,785,500,000.00
- BMRN $3,063,608,000.00
- Revenue This Year
- JHX $16.57
- BMRN $13.32
- Revenue Next Year
- JHX $17.46
- BMRN $9.37
- P/E Ratio
- JHX $33.36
- BMRN $16.23
- Revenue Growth
- JHX N/A
- BMRN 18.36
- 52 Week Low
- JHX $17.91
- BMRN $52.93
- 52 Week High
- JHX $43.57
- BMRN $73.51
- Technical
- Relative Strength Index (RSI)
- JHX 33.81
- BMRN 44.47
- Support Level
- JHX $19.09
- BMRN $52.94
- Resistance Level
- JHX $20.27
- BMRN $56.07
- Average True Range (ATR)
- JHX 0.49
- BMRN 1.52
- MACD
- JHX 0.16
- BMRN -0.26
- Stochastic Oscillator
- JHX 10.76
- BMRN 32.12
About JHX James Hardie Industries plc (Ireland)
James Hardie is a manufacturer of fiber cement-based building products, selling primarily to the residential construction industry. North America is the primary geography, generating about 80% of group earnings. Here, it is the largest manufacturer of fiber cement, which is mainly used for exterior siding on houses. Businesses in Australia, New Zealand, and Europe, make up the rest of earnings.
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.